JP4451930B2 - 一酸化窒素の生成を阻害するテトラサイクリン化合物の使用方法 - Google Patents

一酸化窒素の生成を阻害するテトラサイクリン化合物の使用方法 Download PDF

Info

Publication number
JP4451930B2
JP4451930B2 JP51173598A JP51173598A JP4451930B2 JP 4451930 B2 JP4451930 B2 JP 4451930B2 JP 51173598 A JP51173598 A JP 51173598A JP 51173598 A JP51173598 A JP 51173598A JP 4451930 B2 JP4451930 B2 JP 4451930B2
Authority
JP
Japan
Prior art keywords
cmt
dedimethylaminotetracycline
nitric oxide
mammal
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP51173598A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002513386A5 (enExample
JP2002513386A (ja
Inventor
アショク アール アミン
スティーヴン ビー アブラムソン
ローン エム ゴルーブ
ヌンガヴァラム エス ラママーティー
トーマス エフ マクナマラ
ロバート エイ グリーンワルド
ハワード トラクトマン
Original Assignee
ザ リサーチ ファウンデーション オブ ステイト ユニヴァーシティ オブ ニューヨーク
ホスピタル フォア ジョイント ディジーズス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24802673&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4451930(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ザ リサーチ ファウンデーション オブ ステイト ユニヴァーシティ オブ ニューヨーク, ホスピタル フォア ジョイント ディジーズス filed Critical ザ リサーチ ファウンデーション オブ ステイト ユニヴァーシティ オブ ニューヨーク
Publication of JP2002513386A publication Critical patent/JP2002513386A/ja
Publication of JP2002513386A5 publication Critical patent/JP2002513386A5/ja
Application granted granted Critical
Publication of JP4451930B2 publication Critical patent/JP4451930B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Epoxy Compounds (AREA)
JP51173598A 1996-08-30 1997-08-21 一酸化窒素の生成を阻害するテトラサイクリン化合物の使用方法 Expired - Lifetime JP4451930B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/697,815 1996-08-30
US08/697,815 US5789395A (en) 1996-08-30 1996-08-30 Method of using tetracycline compounds for inhibition of endogenous nitric oxide production
PCT/US1997/014723 WO1998008480A2 (en) 1996-08-30 1997-08-21 Method of using tetracycline compounds for inhibition of nitric oxide production

Publications (3)

Publication Number Publication Date
JP2002513386A JP2002513386A (ja) 2002-05-08
JP2002513386A5 JP2002513386A5 (enExample) 2005-04-07
JP4451930B2 true JP4451930B2 (ja) 2010-04-14

Family

ID=24802673

Family Applications (1)

Application Number Title Priority Date Filing Date
JP51173598A Expired - Lifetime JP4451930B2 (ja) 1996-08-30 1997-08-21 一酸化窒素の生成を阻害するテトラサイクリン化合物の使用方法

Country Status (8)

Country Link
US (2) US5789395A (enExample)
EP (1) EP0966525A4 (enExample)
JP (1) JP4451930B2 (enExample)
KR (1) KR100554859B1 (enExample)
AU (1) AU718234B2 (enExample)
CA (2) CA2670296A1 (enExample)
NZ (1) NZ334512A (enExample)
WO (1) WO1998008480A2 (enExample)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
AU2069597A (en) 1996-03-04 1997-09-22 Genetrace Systems, Inc. Methods of screening nucleic acids using mass spectrometry
EP0907747A1 (en) * 1996-03-15 1999-04-14 Yale University Methods and means of detecting nitric oxide synthase
US5965363A (en) 1996-09-19 1999-10-12 Genetrace Systems Inc. Methods of preparing nucleic acids for mass spectrometric analysis
ATE375403T1 (de) 1996-11-06 2007-10-15 Sequenom Inc Dna-diagnostik mittels massenspektrometrie
JP2001524808A (ja) 1996-12-10 2001-12-04 ジーントレイス・システムズ・インコーポレイテッド 放出可能な不揮発性の質量標識分子
US6160021A (en) * 1997-02-04 2000-12-12 The General Hospital Corporation Method for treating epidermal or dermal conditions
US5773430A (en) * 1997-03-13 1998-06-30 Research Foundation Of State University Of New York Serine proteinase inhibitory activity by hydrophobic tetracycline
DK1041991T3 (da) * 1997-12-19 2008-07-28 Univ New York Ikke-antibakterielle tetracycliner til behandling af multipel sklerose
US7189703B2 (en) * 1998-01-09 2007-03-13 Intracell, Llc Treatment and diagnosis of alzheimer's disease
US6277061B1 (en) * 1998-03-31 2001-08-21 The Research Foundation Of State University Of New York Method of inhibiting membrane-type matrix metalloproteinase
AU763164B2 (en) * 1998-05-08 2003-07-17 University Of Miami Use of tetracyclines for treating meibomian gland disease
PT102160B (pt) * 1998-05-26 2001-04-30 Hovione Sociedade Quimica S A Processo para a preparacao de 4-(des-dimetilamino)-tetraciclinas
US6432934B1 (en) * 1998-08-06 2002-08-13 Advanced Vision Research Methods and compositions for topical treatment of eye surface inflammation and related dry eye disease
US6015804A (en) * 1998-09-11 2000-01-18 The Research Foundation Of State University Of New York Method of using tetracycline compounds to enhance interleukin-10 production
US5977091A (en) * 1998-09-21 1999-11-02 The Research Foundation Of State University Of New York Method of preventing acute lung injury
US6506740B1 (en) 1998-11-18 2003-01-14 Robert A. Ashley 4-dedimethylaminotetracycline derivatives
US6946453B2 (en) 1998-11-18 2005-09-20 Collagenex Pharmaceuticals, Inc. 4-dedimethylaminotracycline derivatives
US6197776B1 (en) * 1999-03-17 2001-03-06 Ernest L. Bonner, Jr. Method for treatment of reactive arthritis or bursitis
EP1171163A1 (en) * 1999-04-27 2002-01-16 Antibody Systems, Inc. Compositions containing tetracyclines for treating hemorrhagic virus infections and other disorders
US6500812B2 (en) 1999-09-14 2002-12-31 Paratek Pharmaceuticals, Inc. 13-substituted methacycline compounds
US6849615B2 (en) 1999-09-14 2005-02-01 Paratek Pharmaceuticals, Inc. 13-substituted methacycline compounds
EP1223937A2 (en) * 1999-10-07 2002-07-24 Novaneuron Inc. Gene necessary for striatal function, uses thereof, and compounds for modulating same
AU3105801A (en) 2000-01-24 2001-07-31 Trustees Of Tufts College Tetracycline compounds for treatment of cryptosporidium parvum related disorders
WO2001052902A1 (en) * 2000-01-24 2001-07-26 Isis Pharmaceuticals, Inc. Antisense modulation of inducible nitric oxide synthase expression
GB0004531D0 (en) * 2000-02-25 2000-04-19 Richards Andrew J M The treatment of respiratory diseases
WO2001074761A1 (en) * 2000-03-31 2001-10-11 Trustees Of Tufts College 7-and 9-carbamate, urea, thiourea, thiocarbamate, and heteroaryl-amino substituted tetracycline compounds
US6613756B2 (en) 2000-05-05 2003-09-02 Wisconsin Alumni Research Foundation Use of tetracycline derivatives in treating multiple sclerosis
US6642270B2 (en) 2000-05-15 2003-11-04 Paratek Pharmaceuticals, Inc. 7-substituted fused ring tetracycline compounds
ATE423221T1 (de) 2000-06-13 2009-03-15 Univ Boston Verwendung von mass-matched nukleotide in der analyse von oligonukleotidmischungen sowie in der hoch-multiplexen nukleinsäuresequenzierung
US20040224927A1 (en) 2000-06-16 2004-11-11 Trustees Of Tufts College 7-N-substituted phenyl tetracycline compounds
US20020132798A1 (en) 2000-06-16 2002-09-19 Nelson Mark L. 7-phenyl-substituted tetracycline compounds
AU2001268475A1 (en) * 2000-06-16 2002-01-02 Trustees Of Tufts College 7-phenyl-substituted tetracycline compounds
KR101027625B1 (ko) 2000-07-07 2011-04-06 파라테크 파마슈티컬스, 인크. 7-치환 테트라사이클린 화합물
US20050143353A1 (en) * 2000-07-07 2005-06-30 Paratek Pharmaceuticals, Inc. 13-Substituted methacycline compounds
EP1303479B1 (en) 2000-07-07 2011-04-06 Trustees Of Tufts College 7-, 8- and 9-substituted tetracycline compounds
DK1679305T3 (da) 2000-07-07 2012-05-29 Tufts College 9-substituerede minocyclinforbindelser
US7094806B2 (en) 2000-07-07 2006-08-22 Trustees Of Tufts College 7, 8 and 9-substituted tetracycline compounds
AU2001288792A1 (en) * 2000-09-06 2002-03-22 Neurotherapeutics, Llc Method of treating neurologic disorders
CA2434693A1 (en) * 2001-01-18 2002-10-17 Genzyme Corporation Ionene polymers and their use as antimicrobial agents
US7045349B2 (en) * 2001-01-23 2006-05-16 Benedict Daniel J Method of islet isolation using process control
WO2002072532A1 (en) 2001-03-13 2002-09-19 Paratek Pharmaceuticals, Inc. 7, 9-substituted tetracycline compounds
AU2002250331A1 (en) * 2001-03-13 2002-09-24 Paratek Pharmaceuticals, Inc. 7-pyrollyl tetracycline compounds and methods of use thereof
JP2004530661A (ja) * 2001-03-14 2004-10-07 パラテック ファーマシューティカルズ インコーポレイテッド 抗真菌剤としての置換テトラサイクリン化合物
CA2440757A1 (en) 2001-03-14 2002-09-19 Michael Draper Substituted tetracycline compounds as synergistic antifungal agents
US20040115261A1 (en) * 2001-04-05 2004-06-17 Ashley Robert A. Controlled delivery of tetracycline compounds and tetracycline derivatives
NZ528197A (en) * 2001-04-05 2007-04-27 Collagenex Pharm Inc Use of a tetracycline compound of treating acne
US7211267B2 (en) 2001-04-05 2007-05-01 Collagenex Pharmaceuticals, Inc. Methods of treating acne
EP2186793A1 (en) * 2001-04-24 2010-05-19 Paratek Pharmaceuticals, Inc. Substituted Tetracycline Compounds
US8088820B2 (en) * 2001-04-24 2012-01-03 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for the treatment of malaria
GB0114672D0 (en) 2001-06-15 2001-08-08 Orthogenics As Pharmaceutical formulations and methods of medical treatment
US20060194773A1 (en) * 2001-07-13 2006-08-31 Paratek Pharmaceuticals, Inc. Tetracyline compounds having target therapeutic activities
EP2332547A1 (en) 2001-07-13 2011-06-15 Paratek Pharmaceuticals, Inc. Tetracyclines for the treatment of inflammatory bowel disease
US20110092677A1 (en) * 2001-08-30 2011-04-21 Biorexis Technology, Inc. Modified transferin-antibody fusion proteins
EP2311796A1 (en) 2002-01-08 2011-04-20 Paratek Pharmaceuticals, Inc. 4-dedimethylamino tetracycline compounds
US6833139B1 (en) 2002-01-09 2004-12-21 Ferndale Laboratories, Inc. Composition and method for the treatment of anorectal disorders
WO2003075857A2 (en) 2002-03-08 2003-09-18 Paratek Pharmaceuticals, Inc. Amino-methyl substituted tetracycline compounds
EA200401232A1 (ru) 2002-03-21 2005-12-29 Пэрэтек Фамэсьютикэлс, Инк. Замещенные соединения тетрациклина, фармацевтическая композиция и способ лечения чувствительного к тетрациклину состояния у субъекта
DE60335093D1 (de) * 2002-03-29 2011-01-05 Univ New York State Res Found Verwendung von nichtantibakteriellen tetrazyklin-analoga und ihren formulierungen für die behandlung von bakteriellen exotoxinen
US6958161B2 (en) 2002-04-12 2005-10-25 F H Faulding & Co Limited Modified release coated drug preparation
US8192749B2 (en) 2003-04-16 2012-06-05 Galderma Laboratories Inc. Methods of simultaneously treating ocular rosacea and acne rosacea
KR101089429B1 (ko) 2002-07-12 2011-12-07 파라테크 파마슈티컬스, 인크. 3, 10, 및 12ａ 치환된 테트라시클린 화합물
EP1531830A4 (en) * 2002-07-12 2007-09-05 Univ New York State Res Found METHOD FOR REDUCING MIRRORATES OF THE C REACTIVE PROTEIN WITH NON-ANTIBACTERIAL TETRACYCLIN FORMULATIONS
US20040044220A1 (en) * 2002-08-22 2004-03-04 University Of Florida Antioxidant and radical scavenging activity of synthetic analogs of desferrithiocin
AU2003287218C1 (en) 2002-10-24 2010-07-15 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for the treatment of malaria
WO2004046109A2 (en) * 2002-11-19 2004-06-03 Genzyme Corporation Ionene oligomers and polymers
WO2004091483A2 (en) 2003-04-07 2004-10-28 Shire Laboratories, Inc. Once daily formulations of tetracyclines
US20040220242A1 (en) * 2003-05-02 2004-11-04 Leland Shapiro Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide induced clinical conditions
EP1656341A1 (en) 2003-07-09 2006-05-17 Paratek Pharmaceuticals, Inc. Prodrugs of 9-aminomethyl tetracycline compounds
KR101228706B1 (ko) 2003-07-09 2013-02-01 파라테크 파마슈티컬스, 인크. 치환된 테트라시클린 화합물
DE10343887B3 (de) * 2003-09-19 2004-12-09 Goodwell International Ltd., Tortola Snowboardbindung
EP1716101A1 (en) * 2004-01-15 2006-11-02 Paratek Pharmaceuticals, Inc. Aromatic a-ring derivatives of tetracycline compounds
US20050176140A1 (en) * 2004-02-10 2005-08-11 Benedict Daniel J. Method and apparatus for cell culture using a two liquid phase bioreactor
TWI261038B (en) * 2004-08-11 2006-09-01 Bo-Cheng Chen Bicycle gear-shifting handgrip
EP2269978A3 (en) 2004-10-25 2011-09-21 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
CA2585418A1 (en) 2004-10-25 2006-05-04 Paratek Pharmaceuticals, Inc. 4-aminotetracyclines and methods of use thereof
US7919483B2 (en) * 2005-06-24 2011-04-05 Medicis Pharmaceutical Corporation Method for the treatment of acne
US8722650B1 (en) 2005-06-24 2014-05-13 Medicis Pharmaceutical Corporation Extended-release minocycline dosage forms
US8252776B2 (en) * 2007-04-02 2012-08-28 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US20080242642A1 (en) 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
CA2616224A1 (en) * 2005-07-21 2007-02-01 Paratek Pharmaceuticals, Inc. 10-substituted tetracyclines and methods of use thereof
CA2673486C (en) * 2006-12-21 2015-09-08 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for treatment of inflammatory skin disorders
EP3045449A1 (en) 2006-12-21 2016-07-20 Paratek Pharmaceuticals, Inc. Tetracycline derivatives for the treatment of bacterial, viral and parasitic infections
JP5395052B2 (ja) * 2007-03-23 2014-01-22 モレキュラー リサーチ センター インコーポレイテッド 炎症を処置するための組成物および方法
WO2008134048A2 (en) * 2007-04-27 2008-11-06 Paratek Pharmaceuticals, Inc. Methods for synthesizing and purifying aminoalkyl tetracycline compounds
EA201070048A1 (ru) * 2007-07-06 2010-10-29 Паратек Фармасьютикалс, Инк. Способы синтеза замещённых соединений тетрациклина (варианты)
TWI585071B (zh) 2008-05-19 2017-06-01 派洛泰克藥物股份有限公司 四環素化合物之甲苯磺酸鹽及同素異形體
EP2307027A4 (en) 2008-07-11 2012-08-15 Neumedics TETRACYCLINE DERIVATIVES WITH REDUCED ANTIBIOTIC ACTIVITY AND NEUROPROTECTIVE PROPERTIES
WO2010017310A1 (en) 2008-08-06 2010-02-11 Medicis Pharmaceutical Corporation Method for the treatment of acne and certain dosage forms thereof
PL3000805T3 (pl) 2008-08-08 2018-04-30 Tetraphase Pharmaceuticals, Inc. C7-fluoro podstawione związki tetracyklinowe
KR101290745B1 (ko) 2010-06-03 2013-07-29 한국해양과학기술원 라말린을 함유하는 염증질환 또는 면역질환의 예방 또는 치료용 약학 조성물
ES2627772T3 (es) 2009-05-08 2017-07-31 Tetraphase Pharmaceuticals, Inc. Compuestos de tetraciclina
WO2011025982A2 (en) 2009-08-28 2011-03-03 Tetraphase Pharmaceuticals, Inc. Tetracycline compounds
ES2621409T3 (es) 2010-03-31 2017-07-04 Tetraphase Pharmaceuticals, Inc. Compuestos policíclicos de tetraciclina
US8524662B2 (en) 2010-12-28 2013-09-03 Depuy Mitek, Llc Compositions and methods for treating joints
US8455436B2 (en) 2010-12-28 2013-06-04 Depuy Mitek, Llc Compositions and methods for treating joints
US8398611B2 (en) 2010-12-28 2013-03-19 Depuy Mitek, Inc. Compositions and methods for treating joints
PT2707003T (pt) 2011-05-12 2019-08-05 Paratek Pharm Innc Sais cristalinos da amida do ácido (4s,4as,5ar,12as)-4-dimetilamino-3,10,12,12a-tetra-hidroxi-7-[(metoxi(metil)amino]-metil]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octa-hidro-naftaceno-2-carboxílico e métodos de utilização dos mesmos
US9561241B1 (en) 2011-06-28 2017-02-07 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for minocycline
US9119793B1 (en) 2011-06-28 2015-09-01 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for doxycycline
US8623839B2 (en) 2011-06-30 2014-01-07 Depuy Mitek, Llc Compositions and methods for stabilized polysaccharide formulations
HK1210593A1 (en) * 2012-07-13 2016-04-29 Paratek Pharmaceuticals, Inc. Tetracycline compounds for treating neurodegenerative disorders
AU2013308504B2 (en) 2012-08-31 2016-11-10 Tetraphase Pharmaceuticals, Inc. Tetracycline compounds
US10842802B2 (en) 2013-03-15 2020-11-24 Medicis Pharmaceutical Corporation Controlled release pharmaceutical dosage forms
US9682099B2 (en) 2015-01-20 2017-06-20 DePuy Synthes Products, Inc. Compositions and methods for treating joints
KR102880712B1 (ko) 2016-10-19 2025-11-03 테트라페이즈 파마슈티컬스, 인코포레이티드 에라바사이클린의 결정질 형태
FR3081559B1 (fr) * 2018-05-28 2020-05-08 Noptrack Procede pour detecter une pathologie par reperage d'une quantite de no produite par le sujet etudie et appareil pour la mise en œuvre dudit procede
WO2020097450A1 (en) 2018-11-09 2020-05-14 Tetraphase Pharmaceuticals, Inc. Polymorphic forms of a compound and uses thereof
FR3103901B1 (fr) * 2019-11-28 2023-02-24 Noptrack Detection d’une espece chimique dans la sueur d’un sujet

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478946A (en) * 1989-06-21 1995-12-26 Abbott Laboratories Guanidino compounds as regulators of nitric oxide synthase
US5216025A (en) * 1989-09-13 1993-06-01 Board Of Regents, The University Of Texas System Nitric oxide synthesis inhibitors for potentiating the action of pressor agents in certain hypotensive patients
US5246971A (en) * 1991-12-16 1993-09-21 Washington University Method of inhibiting nitric oxide formation
US5246970A (en) * 1991-12-16 1993-09-21 Washington University Method of inhibiting nitric oxide formation
US5358969A (en) * 1991-12-16 1994-10-25 Washington University Method of inhibiting nitric oxide formation
GB9200114D0 (en) * 1992-01-04 1992-02-26 Scras Dual inhibitors of no synthase and cyclooxygenase
US5296466A (en) * 1992-02-19 1994-03-22 Board Of Regents, The University Of Texas System Inhibition of nitric oxide-mediated hypotension and septic shock with iron-containing hemoprotein
US5266594A (en) * 1992-05-12 1993-11-30 Dawson Valina L Inhibitors of nitric oxide synthase and use thereof to prevent glutamate neurotoxicity
US5258371A (en) * 1992-05-29 1993-11-02 Kuraray Co., Ltd. Method to reduce connective tissue destruction
WO1994012645A2 (en) * 1992-11-25 1994-06-09 University Of Pittsburgh Of The Commonwealth System Of Higher Education cDNA CLONE FOR HUMAN INDUCIBLE NITRIC OXYDE SYNTHASE AND PROCESS FOR PREPARING SAME
US5449688A (en) * 1993-03-30 1995-09-12 The United States Of America As Represented By The Department Of Health And Human Services Method of treating chronic inflammatory diseases

Also Published As

Publication number Publication date
AU4080897A (en) 1998-03-19
EP0966525A4 (en) 2004-04-14
US5919775A (en) 1999-07-06
CA2264552C (en) 2009-10-13
EP0966525A1 (en) 1999-12-29
WO1998008480A3 (en) 2004-07-01
KR20000035881A (ko) 2000-06-26
NZ334512A (en) 2000-09-29
KR100554859B1 (ko) 2006-02-24
AU718234B2 (en) 2000-04-13
CA2670296A1 (en) 1998-03-05
US5789395A (en) 1998-08-04
CA2264552A1 (en) 1998-03-05
JP2002513386A (ja) 2002-05-08
WO1998008480A2 (en) 1998-03-05

Similar Documents

Publication Publication Date Title
JP4451930B2 (ja) 一酸化窒素の生成を阻害するテトラサイクリン化合物の使用方法
Ihrke et al. The use of fluoroquinolones in veterinary dermatology
Southard et al. Subgingival controlled release of antimicrobial agents in the treatment of periodontal disease
JP2676080B2 (ja) 非抗バクテリア性テトラサイクリン組成物
KR100691654B1 (ko) 테트라시클린 화합물을 이용한 인터루킨-10 생성을촉진하는 방법
Wang et al. Minocycline inhibits LPS-induced retinal microglia activation
Emingil et al. Effect of azithromycin, as an adjunct to nonsurgical periodontal treatment, on microbiological parameters and gingival crevicular fluid biomarkers in generalized aggressive periodontitis
JP4428727B2 (ja) 癌の成長を抑制する方法
Abbott Selective and intelligent use of antibiotics in endodontics
DE69433818D1 (de) Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung
JPH0780774B2 (ja) 薬剤組成物
BR0011000A (pt) Métodos para prevenir ou tratar uma doença associada com depósitos amilóides de ab no cérebro de um paciente, para avaliar um anticorpo quanto á atividade de remoção de uma entidade biológica fisicamente associada com um antìgeno e para detectara um depósito amilóide em um paciente, composição farmacêutica, e, conjunto de diagnóstico
Kirschneck et al. Effects of the highly COX‐2‐selective analgesic NSAID Etoricoxib on human periodontal ligament fibroblasts during compressive orthodontic mechanical strain
Woodward et al. An investigation of uterine nitric oxide production in mares susceptible and resistant to persistent breeding‐induced endometritis and the effects of immunomodulation
BRPI0610125B1 (pt) Composição farmacêutica, kit e utilização de uma composição
Kondreddy et al. Effectiveness of a controlled release chlorhexidine chip (PerioCol™-CG) as an adjunctive to scaling and root planing when compared to scaling and root planing alone in the treatment of chronic periodontitis: A comparative study
Dang et al. Comparative evaluation of efficacy of three treatment modalities–tetracycline fibers, scaling and root planing, and combination therapy: A clinical study
Vicente et al. Modulation of haem oxygenase‐1 expression by nitric oxide and leukotrienes in zymosan‐activated macrophages
TWI245643B (en) Composition for selective cancer chemotherapy
Jorgensen et al. The ins and outs of periodontal antimicrobial therapy
Jendrzejewski et al. Antibiotics and ERCP: in vitro activity of aminoglycosides when added to iodinated contrast agents
RU2179032C1 (ru) Средство для лечения хронического простатита
Bernard et al. Rickettsiosis caused by Rickettsia conorii: treatment with ofloxacin
CN110496128B (zh) 利培酮或帕潘立酮在制备治疗弥漫性大b细胞淋巴瘤的药物中的应用
McRipley et al. Responsiveness of experimental surgical-wound infections to topical chemotherapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040709

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040709

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080507

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080807

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080912

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080908

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081020

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081107

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100105

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100129

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130205

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140205

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term